The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity

Joellen H H Lin, Dragana Novakovic, Christina M. Rizzo, Branislava Zagorac, Mathieu Garand, Anastassia Filipieva, Marlys L. Koschinsky, Michael B. Boffa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

TAFI (thrombin-activatable fibrinolysis inhibitor) is a pro-carboxypepti-dase, encoded by the CPB2 gene in humans that links the coagulation cascade to fibrinolysis and inflammation. The liver is the main source for plasma TAFI, and TAFI expression has been documented in platelets and monocyte-derived macrophages. A recent study reported an alternatively spliced CPB2 mRNA variant lacking exon 7 (Δ7) in HepG2 cells and liver. Another study identified a CPB2 mRNA variant lacking exon 7 and a 52 bp deletion in exon 11 (Δ7+11) in human hippocampus. We have examined alternative splicing of CPB2 mRNA in various cell types by RT-PCR and have assessed the functional properties of TAFI variants encoded by these transcripts by recombinant expression in mammalian cells. We identified the Δ7 exon skipping event in liver, Dami megaka-ryoblasts, THP-1-derived macrophages, peripheral blood mononuclear cells, platelets, testis, cerebellum, and SH-SY5Y neuroblastoma cells. The A11 alternative splicing event was notably absent in liver cells. We also detected a novel exon Δ7+8 skipping event in liver and megakaryocytes. Of note, we detected non-alternatively spliced CPB2 transcripts in brain tissues, suggesting the expression of full-length TAFI in brain. Experiments using cultured mammalian cells transfected with wild-type CPB2-, Δ7-, Δ7+11 -, and_A11 -cDNA revealed that alternatively spliced TAFI is stored inside the cells, cannot be activated by thrombin-thrombomodulin, and does not have TAFIa activity. The alternative splicing events clearly do not give rise to a secreted protein with basic carboxy-peptidase activity, but the intracellular forms may possess novel functions related to intracellular proteolysis.

Original languageEnglish
Pages (from-to)1033-1044
Number of pages12
JournalThrombosis and Haemostasis
Volume109
Issue number6
DOIs
Publication statusPublished - 18 Apr 2013
Externally publishedYes

Fingerprint

Carboxypeptidase B2
Exons
Messenger RNA
Alternative Splicing
Liver
Proteins
Blood Platelets
Macrophages
Thrombomodulin
Megakaryocytes
Hep G2 Cells
Brain
Fibrinolysis
Neuroblastoma
Thrombin
Cerebellum
Proteolysis
Testis
Cultured Cells
Hippocampus

Keywords

  • Alternative splicing
  • Brain
  • Liver
  • Megakaryocytes
  • Monocytes/macrophages
  • Thrombin-activatable fibrinolysis inhibitor (TAFI)

ASJC Scopus subject areas

  • Hematology

Cite this

The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity. / Lin, Joellen H H; Novakovic, Dragana; Rizzo, Christina M.; Zagorac, Branislava; Garand, Mathieu; Filipieva, Anastassia; Koschinsky, Marlys L.; Boffa, Michael B.

In: Thrombosis and Haemostasis, Vol. 109, No. 6, 18.04.2013, p. 1033-1044.

Research output: Contribution to journalArticle

Lin, Joellen H H ; Novakovic, Dragana ; Rizzo, Christina M. ; Zagorac, Branislava ; Garand, Mathieu ; Filipieva, Anastassia ; Koschinsky, Marlys L. ; Boffa, Michael B. / The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity. In: Thrombosis and Haemostasis. 2013 ; Vol. 109, No. 6. pp. 1033-1044.
@article{32ceed460b14435282bf45d7e09e1a67,
title = "The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity",
abstract = "TAFI (thrombin-activatable fibrinolysis inhibitor) is a pro-carboxypepti-dase, encoded by the CPB2 gene in humans that links the coagulation cascade to fibrinolysis and inflammation. The liver is the main source for plasma TAFI, and TAFI expression has been documented in platelets and monocyte-derived macrophages. A recent study reported an alternatively spliced CPB2 mRNA variant lacking exon 7 (Δ7) in HepG2 cells and liver. Another study identified a CPB2 mRNA variant lacking exon 7 and a 52 bp deletion in exon 11 (Δ7+11) in human hippocampus. We have examined alternative splicing of CPB2 mRNA in various cell types by RT-PCR and have assessed the functional properties of TAFI variants encoded by these transcripts by recombinant expression in mammalian cells. We identified the Δ7 exon skipping event in liver, Dami megaka-ryoblasts, THP-1-derived macrophages, peripheral blood mononuclear cells, platelets, testis, cerebellum, and SH-SY5Y neuroblastoma cells. The A11 alternative splicing event was notably absent in liver cells. We also detected a novel exon Δ7+8 skipping event in liver and megakaryocytes. Of note, we detected non-alternatively spliced CPB2 transcripts in brain tissues, suggesting the expression of full-length TAFI in brain. Experiments using cultured mammalian cells transfected with wild-type CPB2-, Δ7-, Δ7+11 -, and_A11 -cDNA revealed that alternatively spliced TAFI is stored inside the cells, cannot be activated by thrombin-thrombomodulin, and does not have TAFIa activity. The alternative splicing events clearly do not give rise to a secreted protein with basic carboxy-peptidase activity, but the intracellular forms may possess novel functions related to intracellular proteolysis.",
keywords = "Alternative splicing, Brain, Liver, Megakaryocytes, Monocytes/macrophages, Thrombin-activatable fibrinolysis inhibitor (TAFI)",
author = "Lin, {Joellen H H} and Dragana Novakovic and Rizzo, {Christina M.} and Branislava Zagorac and Mathieu Garand and Anastassia Filipieva and Koschinsky, {Marlys L.} and Boffa, {Michael B.}",
year = "2013",
month = "4",
day = "18",
doi = "10.1160/TH12-09-0668",
language = "English",
volume = "109",
pages = "1033--1044",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "6",

}

TY - JOUR

T1 - The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity

AU - Lin, Joellen H H

AU - Novakovic, Dragana

AU - Rizzo, Christina M.

AU - Zagorac, Branislava

AU - Garand, Mathieu

AU - Filipieva, Anastassia

AU - Koschinsky, Marlys L.

AU - Boffa, Michael B.

PY - 2013/4/18

Y1 - 2013/4/18

N2 - TAFI (thrombin-activatable fibrinolysis inhibitor) is a pro-carboxypepti-dase, encoded by the CPB2 gene in humans that links the coagulation cascade to fibrinolysis and inflammation. The liver is the main source for plasma TAFI, and TAFI expression has been documented in platelets and monocyte-derived macrophages. A recent study reported an alternatively spliced CPB2 mRNA variant lacking exon 7 (Δ7) in HepG2 cells and liver. Another study identified a CPB2 mRNA variant lacking exon 7 and a 52 bp deletion in exon 11 (Δ7+11) in human hippocampus. We have examined alternative splicing of CPB2 mRNA in various cell types by RT-PCR and have assessed the functional properties of TAFI variants encoded by these transcripts by recombinant expression in mammalian cells. We identified the Δ7 exon skipping event in liver, Dami megaka-ryoblasts, THP-1-derived macrophages, peripheral blood mononuclear cells, platelets, testis, cerebellum, and SH-SY5Y neuroblastoma cells. The A11 alternative splicing event was notably absent in liver cells. We also detected a novel exon Δ7+8 skipping event in liver and megakaryocytes. Of note, we detected non-alternatively spliced CPB2 transcripts in brain tissues, suggesting the expression of full-length TAFI in brain. Experiments using cultured mammalian cells transfected with wild-type CPB2-, Δ7-, Δ7+11 -, and_A11 -cDNA revealed that alternatively spliced TAFI is stored inside the cells, cannot be activated by thrombin-thrombomodulin, and does not have TAFIa activity. The alternative splicing events clearly do not give rise to a secreted protein with basic carboxy-peptidase activity, but the intracellular forms may possess novel functions related to intracellular proteolysis.

AB - TAFI (thrombin-activatable fibrinolysis inhibitor) is a pro-carboxypepti-dase, encoded by the CPB2 gene in humans that links the coagulation cascade to fibrinolysis and inflammation. The liver is the main source for plasma TAFI, and TAFI expression has been documented in platelets and monocyte-derived macrophages. A recent study reported an alternatively spliced CPB2 mRNA variant lacking exon 7 (Δ7) in HepG2 cells and liver. Another study identified a CPB2 mRNA variant lacking exon 7 and a 52 bp deletion in exon 11 (Δ7+11) in human hippocampus. We have examined alternative splicing of CPB2 mRNA in various cell types by RT-PCR and have assessed the functional properties of TAFI variants encoded by these transcripts by recombinant expression in mammalian cells. We identified the Δ7 exon skipping event in liver, Dami megaka-ryoblasts, THP-1-derived macrophages, peripheral blood mononuclear cells, platelets, testis, cerebellum, and SH-SY5Y neuroblastoma cells. The A11 alternative splicing event was notably absent in liver cells. We also detected a novel exon Δ7+8 skipping event in liver and megakaryocytes. Of note, we detected non-alternatively spliced CPB2 transcripts in brain tissues, suggesting the expression of full-length TAFI in brain. Experiments using cultured mammalian cells transfected with wild-type CPB2-, Δ7-, Δ7+11 -, and_A11 -cDNA revealed that alternatively spliced TAFI is stored inside the cells, cannot be activated by thrombin-thrombomodulin, and does not have TAFIa activity. The alternative splicing events clearly do not give rise to a secreted protein with basic carboxy-peptidase activity, but the intracellular forms may possess novel functions related to intracellular proteolysis.

KW - Alternative splicing

KW - Brain

KW - Liver

KW - Megakaryocytes

KW - Monocytes/macrophages

KW - Thrombin-activatable fibrinolysis inhibitor (TAFI)

UR - http://www.scopus.com/inward/record.url?scp=84878644857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878644857&partnerID=8YFLogxK

U2 - 10.1160/TH12-09-0668

DO - 10.1160/TH12-09-0668

M3 - Article

VL - 109

SP - 1033

EP - 1044

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 6

ER -